Drug intelligence / Profile preview

linvoseltamab + nirogacestat

Development stage: Unknown
Lead developer: Regeneron Pharmaceuticals
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous (linvoseltamab), Oral (nirogacestat)

Overview

Linvoseltamab + nirogacestat is an investigational combination therapy for relapsed/refractory multiple myeloma, consisting of **linvoseltamab**, a bispecific monoclonal antibody targeting B-cell maturation antigen (BCMA), and **nirogacestat**, a small-molecule gamma-secretase inhibitor. Linvoseltamab activates cytotoxic T cells against BCMA-expressing myeloma cells, inducing cell death. Nirogacestat inhibits gamma-secretase, which prevents shedding of the BCMA antigen from myeloma cells, thereby maintaining expression of BCMA on the cell surface and potentially increasing sensitivity to BCMA-targeting therapies. The combination aims to enhance antitumor activity by sustaining the target for linvoseltamab. Linvoseltamab is developed and manufactured by Regeneron; nirogacestat is manufactured by SpringWorks Therapeutics. The combination is currently being investigated in clinical trials for multiple myeloma[1][7][2][4].

Brand names: Ogsiveo (nirogacestat)
Other names: linvoseltamab + nirogacestat

Targets

CD3 (T-cell surface glycoprotein CD3)BCMA (B-cell maturation antigen)GSEC (Gamma-Secretase Complex)

Beyond the preview

Go deeper on linvoseltamab + nirogacestat.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on linvoseltamab + nirogacestat.

Explore the full profile